ID   RA
AC   CVCL_C6JY
DR   PRIDE; PXD020079
DR   Wikidata; Q116050157
RX   PubMed=30695232;
RX   PubMed=33592498;
CC   HLA typing: A*02:01,24:02; B*35:03,51:01; C*04:01,14:02; DPA1*01:03,02:07; DPB1*04:01,19:01; DQA1*03:01,04:01; DQB1*03:02,04:02; DRB1*04:01,08:01; DRB4*01:03 (PubMed=33592498).
CC   Omics: HLA class I peptidome analysis by proteomics.
CC   Omics: HLA class II peptidome analysis by proteomics.
CC   Derived from site: In situ; Brain; UBERON=UBERON_0000955.
DI   NCIt; C3058; Glioblastoma
DI   ORDO; Orphanet_360; Glioblastoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
CA   Cancer cell line
DT   Created: 15-12-22; Last updated: 29-06-23; Version: 3
//
RX   PubMed=30695232; DOI=10.1111/febs.14769;
RA   Ramos A.R., Ghosh S., Dedobbeleer M., Robe P.A.J.T., Rogister B.,
RA   Erneux C.;
RT   "Lipid phosphatases SKIP and SHIP2 regulate fibronectin-dependent cell
RT   migration in glioblastoma.";
RL   FEBS J. 286:1120-1135(2019).
//
RX   PubMed=33592498; DOI=10.1074/mcp.RA120.002201; PMCID=PMC8724627;
RA   Forlani G., Michaux J., Pak H., Huber F., Lauret Marie-Joseph E.,
RA   Ramia E., Stevenson B.J., Linnebacher M., Accolla R.S.,
RA   Bassani-Sternberg M.;
RT   "CIITA-transduced glioblastoma cells uncover a rich repertoire of
RT   clinically relevant tumor-associated HLA-II antigens.";
RL   Mol. Cell. Proteomics 20:100032.1-100032.21(2021).
//